Specific genetic changes in small populations of tumor cells can help to make ovarian cancer resistant to treatment, a new study by U.S. researchers revealed.
News
The U.S. Food and Drug Administration (FDA) has granted fast track designation to HDP-101 (pamlectabart tismanitin), a multiple myeloma therapy currently in early clinical…
The U.S. Food and Drug Administration (FDA) has approved Syndax‘s oral therapy Revuforj (revumenib) as a treatment for certain people with acute myeloid leukemia…
Following new, positive data from a Phase 1/2 clinical study, Tango Therapeutics is planning to launch a pivotal trial to test its therapy candidate…
The U.S. Food and Drug Administration (FDA) has approved GSK‘s Blenrep (belantamab mafodotin) for adults with relapsed or refractory multiple myeloma. The approval…
Nearly half of women with hard-to-treat endometrial cancer responded to the investigational therapy Rina-S (rinatabart sesutecan) in a Phase 2 clinical trial, according to new…
People with hard-to-treat myeloma given a combination of Tecvayli (teclistamab) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) — both approved cancer therapies from…
Six of 10 pancreatic cancer patients treated with the investigational drug certepetide along with chemotherapy prior to surgery were alive two years later, according…
Corcept Therapeutics has submitted an application to the European Medicines Agency seeking approval of relacorilant for the treatment of platinum-resistant ovarian cancer. A similar…
Results from a clinical trial testing Exicure‘s therapy candidate burixafor (GPC-100) in stem cell transplants for people with myeloma are expected soon — and the developer…
